Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.46B | |
| -0.61% | +0.81% | +27.25% | +82.72% | 60.14B | |
| -2.54% | -1.65% | +4.86% | +31.72% | 48.15B | |
| -3.02% | -5.20% | +27.94% | +32.51% | 44.25B | |
| +0.31% | +3.02% | +348.95% | +643.82% | 43.99B | |
| -1.96% | -0.33% | +7.04% | +99.46% | 41.61B | |
| +3.32% | +3.49% | +10.10% | +51.23% | 29.97B | |
| +4.77% | +8.00% | +36.77% | +22.78% | 29.31B | |
| -4.86% | -10.66% | -26.27% | +330.06% | 24.93B | |
| Average | -0.04% | -0.08% | +54.00% | +154.28% | 44.09B | |
| Weighted average by Cap. | +0.17% | +0.11% | +58.36% | +145.78% |
Employees
51
